Kisqali
Novartis’ Kisqali delays need for chemo by over 4 years in post-menopausal HR+HER2- metastatic breast cancer
December 9, 2020Research and Development Kisqali, Novartis, breast cancer
Novartis has lifted the curtain on updated Phase 3 data for Kisqali (ribociclib) in the treatment of hormone receptor positive, …
Novartis’ Kisqali approved for NHS Scotland in most common advanced breast cancer
November 12, 2019Manufacturing and Production, Sales and Marketing Cancer, Kisqali, NHS, Novartis, Scotland, breast cancer, pharma
NHS patients in Scotland will soon be able to access Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) after the Scottish Medicines Consortium …
Novartis’ Kisqali reinforces overall survival benefit in postmenopausal HR+/HER2- breast cancer
August 1, 2019Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma
New Phase 3 evidence has emerged on the efficacy of Novartis’ Kisqali (ribociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) in …
NICE greenlights Novartis Kisqali combo in HR+/HER2- advanced breast cancer
July 17, 2019Manufacturing and Production, Medical Communications, Research and Development Cancer, Kisqali, NICE, Novartis, UK, breast cancer, pharma
Novartis’ Kisqali (ribociclib) has secured recommendation from NICE in combination with fulvestrant, meaning the cyclin-dependent kinase 4 and 6 (CDK4/6) …
Novartis’ Kisqali combo boosts survival in HR+/HER2- advanced breast cancer
June 3, 2019Research and Development, Sales and Marketing Cancer, Kisqali, Novartis, breast cancer, pharma
Novartis took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to reveal new Phase 3 …
Novartis’ Kisqali combo rejected by NICE for advanced breast cancer
April 11, 2019Sales and Marketing Kisqali, NHS, NICE, Novartis, pharma
Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, …
Novartis’ Kisqali gains breakthrough status in premenopausal breast cancer
January 3, 2018Research and Development, Sales and Marketing Kisqali, Novartis, biotech, drugs, pharma, pharmaceutical
Novartis has received a major boost in its efforts to broaden use of its CDK4/6 inhibitor, by receiving a breakthrough …
Novartis Kisqali improves PFS in younger women
December 7, 2017Research and Development Kisqali, Novartis, biotech, drugs, pharma, pharmaceutical
A Phase 3 trial looking at the use of Kisqali (ribociclib) to treat premenopausal or perimenopausal women with hormone-receptor positive, …
NICE approves Novartis and Pfizer’s rival breast cancer drugs
November 16, 2017Sales and Marketing Kisqali, Novartis, Pfizer, biotech, drugs, ibrance, pharma, pharmaceutical
NICE has announced that it has given the nod to two new treatments for breast cancer with the approval of …
Novartis’ Kisqali smashes Phase 3 primary endpoint in breast cancer for second time
November 8, 2017Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma
Novartis has revealed that its immunotherapy drug Kisqali (ribociclib) met its primary endpoint of progression-free survival in its second Phase …
Novartis secures first-line FDA approval in breast cancer indication
March 14, 2017Manufacturing and Production, Sales and Marketing Kisqali, Novartis, breast cancer
The FDA has approved Kisqali (ribociclib) in combination with letrozole for the first-line treatment of postmenopausal women with hormone receptor …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
